New data further reinforce Roche’s OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis
75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease activity two years after switching to OCREVUS in open-label Phase IIIb CASTING study 97% persistence and strong adherence to OCREVUS treatment and twice-yearly dosing schedule from real-world data OCREVUS is the first and only treatment approved... Read more